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ABSTRACT
Multiple Myeloma (MM) is a B-cell malignancy characterized by the accumulation 
of clonal plasma cells in the bone marrow, with drug resistance being a major cause of 
therapeutic failure. We established a carfilzomib-resistant derivative of the LP-1 MM 
cell line (LP-1/Cfz) and found that the transcription factor NF-E2 p45-related factor 2 
(Nrf2; gene symbol NFE2L2) contributes to carfilzomib resistance. The mechanism of 
Nrf2 activation involved enhanced translation of Nrf2 as well as its positive regulator, 
the autophagy receptor sequestosome 1 (SQSTM1)/p62. The eukaryotic translation 
initiation factor gene EIF4E3 was among the Nrf2 target genes upregulated in LP-1/
Cfz cells, suggesting existence of a positive feedback loop. In line with this, we found 
that siRNA knockdown of eIF4E3 decreased Nrf2 protein levels. On the other hand, 
elevated SQSTM1/p62 levels were due at least in part to activation of the PERK-
eIF2α pathway. LP-1/Cfz cells had decreased levels of reactive oxygen species as 
well as elevated levels of fatty acid oxidation and prosurvival autophagy. Genetic 
and pharmacologic inhibition of the Nrf2-EIF4E3 axis or the PERK-eIF2α pathway, 
disruption of redox homeostasis or inhibition of fatty acid oxidation or autophagy 
conferred sensitivity to carfilzomib. Our findings were supported by clinical data 
where increased EIF4E3 expression was predictive of Nrf2 target gene upregulation 
in a subgroup of patients with chemoresistant minimal residual disease and relapsed/
refractory MM. Thus, our data offer a preclinical rationale for including inhibitors of 
the SQSTM1/p62-Nrf2 pathway to the treatment regimens for certain advanced stage 
MM patients.
INTRODUCTION
Multiple myeloma (MM) is a B cell malignancy 
characterized by the clonal expansion of neoplastic plasma 
cells in the bone marrow. The introduction of novel agents 
such as proteasome inhibitors and immunomodulatory 
drugs has prolonged the lives of patients with MM over 
the past decade [1]. The first-in-class proteasome inhibitor 
bortezomib provided proof-of-principle that proteasome 
inhibition is an important therapeutic target in MM, 
leading to its FDA approval as frontline therapy in June 
2008 [2]. Despite overall response rates of 100% in the 
setting of newly diagnosed disease [3], most MM patients 
ultimately relapse because the MM cells develop resistance 
to the treatment [4, 5]. Carfilzomib, a second-generation 
proteasome inhibitor that exhibits enhanced selectivity for 
the proteasome [6], received full approval from the FDA 
for the treatment of patients with relapsed/refractory MM 
in January 2016 [7]. However, the overall response rate 
to carfilzomib in the pivotal phase 2 clinical trial was less 
than 25% [8]. Furthermore, in a subsequent phase 3 study 
— in which overall survival was the primary endpoint 
[9] — carfilzomib monotherapy failed to significantly 
improve the survival of relapsed/refractory MM patients 
compared to those who received best supportive care (10.2 
months vs 10.0 months) (ClinicalTrials.gov Identifier: 
                  Priority Research Paper
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NCT01302392). These results indicate that the majority 
of MM cells that became resistant to bortezomib were 
also resistant to carfilzomib. Clearly, to extend the life 
expectancy of patients with this disease, it is essential 
to characterize the mechanisms conferring resistance to 
proteasome inhibitors. 
To begin to understand the underlying processes that 
might be relevant to clinical carfilzomib resistance in MM, 
we previously established carfilzomib-resistant derivatives 
of MM cell lines, KMS-11/Cfz and KMS-34/Cfz [10, 
11]. In both cases, prosurvival autophagy was shown to 
contribute to carfilzomib resistance mediated, in part, via 
transcriptional upregulation of the SQSTM1 gene encoding 
sequestosome 1/p62 (SQSTM1/p62) [11]. SQSTM1/p62 
is a multifunctional scaffold protein that interacts with 
various signaling molecules and serves as a ubiquitin-
binding cargo receptor connecting the proteasomal and 
autophagic protein degradation pathways [12]. Another 
important function of SQSTM1/p62 is activation of the 
transcription factor nuclear factor-erythroid 2 (NF-E2)-
related factor 2 (Nrf2; gene symbol NFE2L2) in the 
Keap1-Nrf2 signaling pathway [13, 14]. The Keap1-
Nrf2 pathway maintains cellular redox homeostasis by 
inducing antioxidant and detoxification genes and by 
modulating energy metabolism [15]. A growing body of 
evidence implicates activation of the Keap1-Nrf2 pathway 
as a contributor to therapy resistance [16] but, to our 
knowledge, its role in conferring resistance to carfilzomib 
in MM cells has not been described.
The Keap1-Nrf2 pathway is tightly regulated at 
multiple levels, the precise details of which are currently 
being elucidated [17]. Under basal conditions, Nrf2 
monomers are sequestered in cytoplasmic complexes 
through two-site binding to Keap1 homodimers which 
target Nrf2 for continuous ubiquitination and proteasomal 
degradation [18]. In response to oxidative stress, the 
Keap1 molecules are modified such that ubiquitination 
of Nrf2 is inhibited and it remains bound to the complex 
[19, 20]. In a variation on this theme, overexpressed 
SQSTM1/p62 binds to and competitively prevents Keap1 
from interacting with one of the Nrf2 sites, effecting 
a conformational change in the complex which leads 
to impaired ubiquitination of associated Nrf2 [13, 14]. 
In both scenarios, newly synthesized Nrf2 escapes 
cytoplasmic sequestration by Keap1 and is free to 
translocate to the nucleus and regulate gene expression. 
Of relevance in this regard, a number of reports have 
indicated that Nrf2 expression is subject to diverse 
mechanisms of translational control [21-25].
Nrf2 activity can also be modulated by other 
mechanisms [26-29]. For example, nuclear translocation 
and activation of Nrf2 is enhanced by phosphorylation 
by the PERK protein kinase [26, 27]. PERK is activated 
upon accumulation of misfolded/unfolded proteins in 
the endoplasmic reticulum which results in the induction 
of an “unfolded protein response” (UPR) [30]. The best 
characterized function of PERK on UPR induction is to 
provide a protective advantage to the cell by attenuating 
global protein translation via inhibitory phosphorylation of 
eukaryotic translation initiation factor-2α (eIF2α) [31, 32]. 
Phosphorylation of eIF2α also results in the preferential 
translation of certain mRNAs containing upstream open 
reading frames (uORFs), the prototypical example of 
which is activating transcription factor 4 (ATF4) [33]. 
During this phase of the UPR, ATF4 and Nrf2 coregulate 
transcription of some cytoprotective genes [34, 35]. 
However, if proteostasis is not restored, ATF4 induces 
a cell death program involving the CCAAT/enhancer-
binding protein homologous protein (CHOP) transcription 
factor [36]. 
Here we report the establishment of a new 
carfilzomib-resistant derivative of the LP-1 MM cell 
line, LP-1/Cfz, in which carfilzomib resistance was 
characterized by induction of prosurvival autophagy as 
well as Nrf2 pathway activation associated with elevated 
SQSTM1/p62 levels. Unlike carfilzomib-resistant KMS-
11/Cfz and KMS-34/Cfz cells, increased SQSTM1/p62 
levels were not due to transcriptional upregulation of the 
SQSTM1 gene [11]. Rather, the higher levels of SQSTM1/
p62 were due to increased translation dependent in part 
on activation of the PERK-eIF2α axis. Comparative 
analysis with KMS-11/Cfz cells revealed Nrf2 target gene 
induction as well but only LP-1/Cfz cells were sensitized 
to carfilzomib by inhibition of the PERK-eIF2α signaling 
cascade. Additionally, LP-1/Cfz cells exhibited increased 
Nrf2 synthesis associated with elevated expression of 
Nrf2 targets involved in translation initiation, in particular, 
EIF4E3 encoding an atypical eukaryotic translation 
initiation factor family member recently demonstrated 
to mediate context-specific translation in diffuse large 
B-cell lymphoma [37, 38]. Moreover, gene set enrichment 
analysis (GSEA) of gene expression profiling data from 
MM patient samples showed that increased EIF4E3 
expression was predictive of Nrf2 activation in some 
chemoresistant minimal residual disease and relapsed/
refractory MM cases. These findings have elucidated 
further complexities of the proteostasis network in MM 
cells and provide preclinical rationale for therapeutic 
development of SQSTM1/p62-Nrf2 inhibitors as a means 
to overcome proteasome inhibitor resistance in a subgroup 
of advanced stage MM patients.
RESULTS
GSEA identifies Nrf2 pathway activation in 
carfilzomib-resistant MM cell lines
The carfilzomib-resistant LP-1/Cfz cell line was 
established by continuous culture of the LP-1 MM cell 
line [39] in stepwise increasing concentrations of the 
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Figure 1: Different sets of Nrf2 target genes are upregulated in LP-1/Cfz and KMS-11/Cfz cells. A. GSEA enrichment plot 
and heat map of the leading edge subset of Nrf2 target genes upregulated in LP-1/Cfz (Cfz) versus parental LP-1 (Parent) cells (triplicate 
samples). Selected Nrf2 targets that are coregulated by ATF4 are indicated with asterisks. B. GSEA enrichment plot and heat map of the 
leading edge subset of Nrf2 target genes upregulated in KMS-11/Cfz (Cfz) versus parental KMS-11 (Parent) cells (triplicate samples). 
Prototypical Nrf2 targets are indicated with asterisks. Probe sets for the SQSTM1 gene are highlighted. Some Nrf2 targets (e.g., TDO2 and 
GLA) were upregulated in both LP-1/Cfz and in KMS-11/Cfz cells. Gene set: NFE2L2.V2 (M2870). NES, normalized enrichment score.
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drug (4 nM to 12 nM) over an 18 week period according 
to a previously published protocol used to derive the 
carfilzomib-resistant MM cell lines, KMS-11/Cfz and 
KMS-34/Cfz [11] (Figure S1). As observed for KMS-
11/Cfz and KMS-34/Cfz cells, LP-1/Cfz cells retained 
resistance to carfilzomib even when tested after removal 
of selective pressure for approximately 8 weeks. Gene 
expression profiling was performed on LP-1/Cfz and 
parental LP-1 cells, and GSEA was used to identify 
differentially overrepresented pathways and processes 
associated with carfilzomib resistance shared between 
LP-1/Cfz cells and the KMS-11/Cfz and KMS-34/Cfz cell 
lines [11]. 
We first applied GSEA to examine gene sets from 
the C3:TFT (transcription factor targets) subcollection of 
the Molecular Signatures Database (MSigDB). Binding 
site motifs for the “cap ‘n’ collar” transcription factors 
NF-E2 (V$NFE2_01) and Nrf2 (V$NRF2_Q4) that 
recognize a similar AP1-like core consensus sequence 
(TGA(G/C/T)TCA) [40] were significantly enriched in 
genes with increased expression in LP-1/Cfz and KMS-
11/Cfz cells (Figure S2). Although NF-E2 expression is 
restricted to erythroid cells, Nrf2 is broadly expressed 
and activated in response to stress [41, 42]. In line with 
Nrf2 activation in both carfilzomib-resistant MM models, 
significant enrichment of Nrf2 target genes (NFE2L2.V2 
gene set) was observed when GSEA was applied to the C6 
(oncogenic signatures) collection of MSigDB (Figure 1). 
GSEA detects coordinated expression changes in 
groups of genes by taking all genes into account, even if 
individual representatives of the groups exhibit modest 
changes [43]. In a second, complementary approach, we 
employed fold change (FC) cutoffs to compare similar 
numbers of differentially expressed genes in LP-1/Cfz 
(FC ≥ 1.7; 896 probe sets) and KMS-11/Cfz cells (FC 
≥ 1.4; 887 probe sets). Transcription factor binding site 
Table 1: Overrepresented transcription factor binding site (TFBS) motifs in genes with increased expression in LP-1/
Cfz and KMS-11/Cfz cells*
A. LP-1/Cfz cells
TFBS JASPAR ID Class Family Fisher Score
Arnt::Ahr MA0006.1 Zipper-Type Helix-Loop-Helix 27.7
Hand1::Tcfe2a MA0092.1 Zipper-Type Helix-Loop-Helix 26.2
SP1 MA0079.2 Zinc-coordinating BetaBetaAlpha-zinc finger 24.3
AP1 MA0099.2 Zipper-Type Leucine Zipper 24.1
Nkx3-2 MA0122.1 Helix-Turn-Helix Homeo 24.0
MEF2A MA0052.1 Other Alpha-Helix MADS 23.4
TBP MA0108.2 Beta-sheet TATA-binding 23.0
NFATC2 MA0152.1 Ig-fold Rel 21.9
MZF1_5-13 MA0057.1 Zinc-coordinating BetaBetaAlpha-zinc finger 21.8
NFE2L2 MA0150.1 Zipper-Type Leucine Zipper 21.4
B. KMS-11/Cfz cells
TFBS JASPAR ID Class Family Fisher Score
NFE2L2 MA0150.1 Zipper-Type Leucine Zipper 22.7
NFYA MA0060.1 Other Alpha-Helix NFY CCAAT-binding 17.3
Spz1 MA0111.1 Other Other 14.2
Foxa2 MA0047.2 Winged Helix-Turn-Helix Forkhead 13.4
INSM1 MA0155.1 Zinc-coordinating BetaBetaAlpha-zinc finger 13.2
RELA MA0107.1 Ig-fold Rel 13.0
REL MA0101.1 Ig-fold Rel 12.7
Esrrb MA0141.1 Zinc-coordinating      Hormone-nuclear Receptor 12.5
FEV MA0156.1 Winged Helix-Turn-Helix Ets 12.5
CEBPA MA0102.2 Zipper-Type Leucine Zipper 12.4
*Identified by oPOSSUM-3 Single Site Analysis using JASPAR CORE vertebrate profiles (minimum information content = 
8 bits; matrix score threshold: 85%) and ranked by Fisher score. Search regions: 5,000 bp upstream and 5,000 bp downstream 
of transcription start sites. The NFE2L2 binding site motif was identified in both LP-1/Cfz and KMS-11/Cfz upregulated gene 
sets. Fisher scores reflect the number of genes containing the predicted TFBS.
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motif discovery was carried out using the oPOSSUM-3 
Single Site Analysis tool and the JASPAR CORE 
vertebrate database [44]. NFE2L2 was the highest-
scoring motif in KMS-11/Cfz cells and the only motif in 
common among the top ten ranked transcription factor 
binding sites overrepresented in the promoter regions of 
the upregulated genes in both carfilzomib-resistant MM 
models (Table 1). This result was notable because an 
Nrf2 ChIP-seq dataset was one of the data sources used to 
validate the performance of the oPOSSUM-3 program [41, 
44]. The Nrf2 ChIP-seq dataset comprised basal (Nrf2-/-) 
and inducible (Keap1-/-) direct binding targets of Nrf2 in 
mouse embryo fibroblasts [41]. We combined this dataset 
with Nrf2 direct binding targets identified by ChiP-seq 
experiments in human lymphoblastoid cells after treatment 
with the dietary isothiocyanate, sulforaphane [40]. Using 
GeneSpring analysis software, we found significant 
enrichment of these Nrf2 direct binding targets in the 
differentially expressed genes in LP-1/Cfz cells (102 out 
of 896 probe sets; P < 10-31) and KMS-11/Cfz cells (107 
out of 887 probe sets; P < 10-31) (see Table S1 for the probe 
set lists). Moreover, there was also significant overlap 
of the differentially expressed genes in the carfilzomib-
resistant MM cells and genes that were downregulated in 
human lymphoblastoid cells after sulforaphane treatment 
— LP-1/Cfz cells (72 out of 896 probe sets; P < 10-20) and 
KMS-11/Cfz cells (68 out of 887 probe sets; P < 10-20) — 
which may represent indirect Nrf2 targets (see Table S2 
for the probe set lists).
Strikingly, different Nrf2 target genes were 
upregulated in LP-1/Cfz and KMS-11/Cfz cells. 
Prototypical cytoprotective Nrf2 targets, as exemplified 
by NQO1 [15], were significantly upregulated in KMS11/
Cfz cells [11] but not in LP-1/Cfz cells (Figure 1; Table 
S1). These findings suggested differential levels of 
Nrf2 activation and/or that the Nrf2-interacting partners 
might be different in the two carfilzomib-resistant MM 
model systems. In support of the latter possibility, GSEA 
indicated activation of a prosurvival ATF4 target gene 
response in LP-1/Cfz cells (Figure S3A, S3B). GSEA 
also showed enrichment of HER2/ERBB2-related 
signatures in LP-1/Cfz cells when the C2:CP (canonical 
pathways) subcollection of MSigDB was queried (Figure 
S3C, S3D). Both factors were previously reported to 
cooperate with Nrf2 and modulate specificity of Nrf2 
target gene activation [35, 36, 45, 46]. In particular, 
a number of the Nrf2 targets upregulated in LP-1/Cfz 
cells (indicated in Figure 1A) were previously shown to 
be directly coregulated by ATF4 [34, 47]. Regardless of 
the different transcriptional outcomes, taken together, 
the data implicated activation of Nrf2 pathways in the 
acquisition of carfilzomib resistance in both MM models. 
In the following experiments, we concentrated mainly 
on elucidating the molecular mechanisms and potential 
functional significance of Nrf2 pathway activation in 
LP-1/Cfz cells.
The autophagy-related gene GABARAPL1 is an 
Nrf2 target upregulated in carfilzomib-resistant 
MM cells
We verified the microarray data for selected Nrf2 
targets in LP-1/Cfz cells by real-time reverse transcription 
polymerase chain reaction (qRT-PCR) assay and western 
blot analysis (Figure S4; see also Figure 2C and Figure 
9C). We noted that several of the novel Nrf2 targets 
are involved in translational control mechanisms; for 
example, EEF1A2, EIF4E3, RND3/RhoE (Table S1A) and 
FAM129A/Niban (Table S2A). EEF1A2 is a translation 
elongation factor gene that was previously shown to 
promote survival of mouse plasmacytoma cells [48], 
whereas EIF4E3, RND3/RhoE and FAM129A/Niban 
encode proteins that participate in various facets of cap-
dependent translation initiation (described in more detail 
below) [38, 49, 50]. 
Of the validated genes, we focused initially on 
the autophagy-related gene GABARAPL1 [51] since 
it was also significantly upregulated in KMS-11/Cfz 
cells (Table S1B). Indeed, inspection of the enriched 
V$NFE2_01 transcription factor motif gene set indicated 
that GABARAPL1 was the top-ranked upregulated Nrf2 
target in common between LP-1/Cfz and KMS-11/
Cfz cells (Figure 2A). In this regard, it was noteworthy 
that the KEGG autophagy gene set was among the 
significantly enriched gene sets in the MSigDB C2:CP 
(canonical pathways) collection identified by combined 
pairwise comparison of LP-1/Cfz and KMS-11/Cfz versus 
parental LP-1 and KMS-11 cells, and GABARAPL1 was 
the top-ranked gene in this instance as well (Figure 2B). 
To investigate whether GABARAPL1 is an Nrf2-binding 
target in LP-1/Cfz and KMS-11/Cfz cells, we performed 
ChIP-qPCR analysis on the promoter region of the 
GABARAPL1 gene. 
An evolutionarily conserved Nrf2 motif was 
identified in the GABARAPL1 promoter region by 
the ConTra v2 transcription factor binding site motif 
discovery program using position weight matrices from 
both the JASPAR CORE and TRANSFAC database 
libraries [52] (Figure S5A). Of note, this motif coincided 
with an NF-E2 ChIP-seq binding site identified in K562 
erythroid cells by the ENCODE project (Figure S5B). 
Using primers flanking this site, we found specific 
enrichment of Nrf2-precipitated chromatin in comparison 
to the unrelated antibody control precipitation in both MM 
cell lines, increased binding of which was observed in the 
carfilzomib-resistant derivatives (Figure 2D). This result 
is congruent with previous findings of substantial overlap 
of functional Nrf2 and NF-E2 binding sites at the genome-
wide and individual gene levels [40, 42]. Thus, the data 
support the notion that GABARAPL1 is a direct Nrf2 target 
gene in LP-1/Cfz and KMS-11/Cfz cells. 
GABARAPL1 is involved in selective autophagy 
through its interaction with ubiquitin-binding cargo 
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Figure 2: The autophagy-related gene GABARAPL1 is an Nrf2 binding target upregulated in LP-1/Cfz and KMS-11/
Cfz cells. A. GSEA enrichment plot and heat map of the leading edge subset of genes upregulated in both LP-1/Cfz and KMS-11/Cfz 
cells (triplicate samples) whose promoter regions contain the NF-E2 motif. Gene set: V$NFE2_01 (M1608). The top-ranked probe sets 
corresponded to GABARAPL1. B. GSEA enrichment plot and heat map of the leading edge subset of autophagy pathway genes upregulated in 
both LP-1/Cfz and KMS-11/Cfz cells. The top-ranked probe sets corresponded to GABARAPL1. Gene set: KEGG Regulation of autophagy 
(M6382; KEGG Pathway hsa04140). C. qRT-PCR analysis was performed to validate the differential expression of GABARAPL1 mRNA 
in LP-1/Cfz (Cfz) versus parental LP-1 (L) cells (mean values of three qRT-PCR experiments). See Table S1A for expression changes 
determined from the microarray data. D. Increased binding of Nrf2 to the GABARAPL1 promoter region indicated in Figure S5 in LP-1/
Cfz and KMS-11/Cfz cells as determined by ChIP-qPCR. E. Fluorescence histograms of LP-1/Cfz and parental LP-1 cells stained with the 
Cyto-ID autophagy detection reagent. F. Cells were treated with the indicated concentrations of carfilzomib for 72 hours in the absence or 
presence of chloroquine (10 μM) and cell viability was determined by alamarBlue assay. *, P < 0.001 vs carfilzomib alone (n = 3).
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receptors such as SQSTM1/p62 [53] and it is essential 
during the late stages of autophagosome maturation 
[54]. Previously, we showed that increased autophagic 
flux contributes to carfilzomib resistance in KMS-11/Cfz 
cells [11]. Increased staining intensity with the Cyto-ID 
autophagy detection reagent revealed that LP-1/Cfz cells 
also had higher steady state levels of autophagosomes 
(Figure 2E), indicating that activation of the Nrf2-
GABARAPL1 axis correlates with increased autophagic 
activity [55]. We also previously demonstrated that 
inhibition of autophagy by chloroquine treatment, which 
increases lysosomal pH and blocks autophagosome-
lysosome fusion, sensitized KMS-11/Cfz cells to 
carfilzomib [11]. Cotreatment with chloroquine likewise 
Figure 3: LP-1/Cfz cells exhibit increased FAO. A. Oxygen consumption rate (OCR) was measured using the Seahorse XF24 
Extracellular Flux Analyzer. FAO was determined by XF Cell Mito Stress Test using the XF Palmitate-BSA FAO substrate in the absence 
or presence of etomoxir (Eto), an inhibitor of carnitine palmitoyltransferase-1, the rate limiting enzyme in FAO. The ATP synthase inhibitor 
oligomycin (Oligo), the uncoupler carbonyl cyanide 4-(trifluoromethoxy) phenylhydrazone (FCCP), and the complex I and III inhibitors 
rotenone and antimycin A (Rtn/AA) were injected at the indicated times. The green arrow indicates the difference in maximal respiration 
— due to FAO — when LP-1/Cfz cells were treated with FCCP in the absence or presence of Eto. B. Average increase in FAO in LP-1/Cfz 
versus parental LP-1 cells (n = 3). C. Oxidation of fatty acids was determined in KMS-11/Cfz and KMS-11 cells as described in A. D. No 
change in FAO in KMS-11/Cfz versus parental KMS-11 cells (n = 3).
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diminished carfilzomib resistance in LP-1/Cfz cells 
(Figure 2F), indicating that prosurvival autophagy 
contributes to acquired carfilzomib resistance in this MM 
cell line similarly to KMS-11/Cfz cells.
LP-1/Cfz cells exhibit increased antioxidant 
capacity due to altered intermediary metabolism
As mentioned above, Nrf2 targets directly involved 
in reactive oxygen species (ROS) detoxification were 
not significantly upregulated in LP-1/Cfz cells by 
comparison to parental LP-1 cells. However, examination 
of the microarray data revealed that a number of these 
prototypical Nrf2 target genes (including NQO1, GCLC, 
GCLM, GPX4, GSR, GSTM1) are already highly expressed 
in LP-1 cells. NQO1 ((NAD(P)H:quinone oxidoreductase 
1), GSR (glutathione reductase) and other antioxidant-
associated enzymes regulated by Nrf2 require NADPH as 
a reducing cofactor [15]. Accordingly, Nrf2 also regulates 
several NADPH-generating enzymes. Specifically, Nrf2 
facilitates NADPH production by directing carbon flux 
through the pentose phosphate pathway [56]. Consistent 
with the hypothesis that Nrf2 is activated in LP-1/Cfz 
as well as in KMS-11/Cfz cells, NADPH levels were 
increased concomitant with upregulation of KEGG 
pentose phosphate pathway genes in both models (Figure 
S6). 
It is becoming increasingly appreciated that Nrf2 
also affects multiple aspects of intermediary metabolism 
indirectly [15], including mitochondrial fatty acid 
oxidation (FAO) [57]. Of note, during the metabolic shift 
towards FAO, activation of autophagy hydrolyzes lipids 
into fatty acids for fuel [58]. Considering that FAO is 
Figure 4: LP-1/Cfz and KMS-11/Cfz cells contain lower levels of hydrogen peroxide-associated ROS than parental 
LP-1 and KMS-11 cells following carfilzomib treatment. A. LP-1/Cfz and parental LP-1 cells were treated for 18 hours with the 
indicated concentrations of carfilzomib (Cfz) and cellular hydrogen peroxide (H2O2) levels were quantified by flow cytometry using the 
redox-sensitive CM-H2DCFDA fluorescent dye. B. KMS-11/Cfz and parental KMS-11 cells were treated for 18 hours with the indicated 
concentrations of carfilzomib and cellular hydrogen peroxide (H2O2) levels were quantified by flow cytometry using the redox-sensitive 
CM-H2DCFDA fluorescent dye.
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an important source of NADPH in leukemic cells [59], 
we examined whether rates of FAO were increased in 
carfilzomib-resistant LP-1/Cfz and KMS-11/Cfz cells. 
Increased FAO was observed in LP-1/Cfz versus parental 
LP-1 cells (Figure 3A, 3B). By comparison, basal rates of 
FAO were already elevated in parental KMS-11 cells and 
there was no further increase in KMS-11/Cfz cells (Figure 
3C, 3D). 
Considered together, the gene expression profiling 
and functional assays supporting increased NADPH 
production and/or upregulation of genes that detoxify ROS 
suggested that LP-1/Cfz and KMS-11/Cfz cells would 
exhibit enhanced Nrf2-mediated antioxidant capacity. 
To examine this, we measured ROS generation using the 
fluorescent redox-sensitive dyes CM-H2DCFDA, which 
is specific for hydrogen peroxide, and MitoSOX Red, 
which is selective for superoxide [60]. Cells were treated 
with varying concentrations of carfilzomib and ROS 
levels were quantified by flow cytometry. Lower levels 
of ROS were generated in LP-1 cells compared to KMS-
11 cells under all conditions; at the highest carfilzomib 
concentrations, both hydrogen peroxide (Figure 4) and 
superoxide (Figure 5) levels were reduced by more than 
70% in the carfilzomib-resistant derivatives versus their 
parental counterparts.
To determine whether antioxidant defense conferred 
protection to carfilzomib in these MM models and whether 
there was a contribution of FAO, the cells were cotreated 
with carfilzomib and either (S)-4-carboxyphenylglycine, 
an inhibitor of xCT (a subunit of the xc
- cystine antiporter 
involved in glutathione homeostasis encoded by the 
SLC7A11 gene; see Figure 1A) [34] or etomoxir, an 
inhibitor of carnitine palmitoyltransferase-1 (the rate 
limiting enzyme in FAO; see Figure 3) [61]. Cotreatment 
with either inhibitor resulted in enhanced sensitivity of 
the resistant cells to carfilzomib (Figure 6), indicating that 
Figure 5: LP-1/Cfz and KMS-11/Cfz cells contain lower levels of superoxide than parental LP-1 and KMS-11 cells 
following carfilzomib treatment. A. LP-1/Cfz and parental LP-1 cells were treated for 18 hours with the indicated concentrations of 
carfilzomib (Cfz) and superoxide (O2
.-) levels were quantified by flow cytometry using the redox-sensitive MitoSOX Red fluorescent dye. 
B. KMS-11/Cfz and parental KMS-11 cells were treated for 18 hours with the indicated concentrations of carfilzomib and superoxide (O2
.-) 
levels were quantified by flow cytometry using the redox-sensitive MitoSOX Red fluorescent dye.
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the glutathione-based antioxidant system contributes to 
carfilzomib resistance in these MM models and that FAO 
is a potential source of reducing equivalents underlying 
the increased ROS defense.
Finally, to directly test whether Nrf2 activity 
contributes to carfilzomib resistance, we transfected 
LP-1/Cfz and parental LP-1 cells with two previously 
validated Nrf2 siRNAs and a control siRNA with no 
known mammalian homology [62, 63]. We confirmed 
that Nrf2 mRNA was knocked down ~45-65% by qRT-
PCR. This was accompanied by an ~30-45% decrease in 
GABARAPL1 mRNA levels (Figure 7A). As illustrated 
in Figure 7B, both Nrf2 siRNAs sensitized LP-1/Cfz cells 
to carfilzomib.
Activation of the PERK-eIF2α axis contributes to 
SQSTM1/p62 synthesis and carfilzomib resistance 
in LP-1/Cfz cells
Next, we focused on the molecular mechanisms 
underlying Nrf2 activation in LP-1/Cfz cells. Nrf2 mRNA 
levels were not significantly increased. However, western 
blot analyses showed significantly higher Nrf2 protein 
levels in the high salt (nuclear) fraction of LP-1/Cfz cell 
lysates compared to parental LP-1 cell lysates (P < 0.001) 
(Figure 7C). Immunofluorescence confocal microscopy 
confirmed that Nrf2 had a predominantly perinuclear 
and nuclear localization in LP-1/Cfz cells (Figure 7D) 
Figure 6: Inhibition of glutathione homeostasis or FAO sensitizes LP-1/Cfz and KMS-11/Cfz cells to carfilzomib. A. 
Treatment with (S)-4-carboxyphenylglycine (CPG), an inhibitor of xCT (a subunit of the xc
- cystine antiporter involved in glutathione 
homeostasis encoded by the SLC7A11 gene) sensitizes LP-1/Cfz cells (left graph) and KMS-11/Cfz cells (right graph) to carfilzomib. Cells 
were treated with the indicated concentrations of carfilzomib for 72 hours in the absence or presence of CPG (0.2 mM) and cell viability 
was determined by alamarBlue assay. *, P < 0.001 vs carfilzomib alone (n = 3). B. Treatment with etomoxir, an inhibitor of carnitine 
palmitoyltransferase-1 (the rate limiting enzyme in FAO), sensitizes LP-1/Cfz cells (left graph) and KMS-11/Cfz cells (right graph) to 
carfilzomib. Cells were treated with the indicated concentrations of carfilzomib for 72 hours in the absence or presence of etomoxir (20 μM) 
and cell viability was determined by alamarBlue assay. *, P < 0.001 vs carfilzomib alone (n = 3).
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[64]. Moreover, treatment with trigonelline, an inhibitor 
of Nrf2 nuclear import [63], sensitized LP-1/Cfz cells to 
carfilzomib (Figure 7E). Steady state Keap1 levels were 
not reduced in LP-1/Cfz cells compared to parental LP-1 
cells (Figure 7F). Unexpectedly, however, despite the fact 
that SQSTM1 mRNA levels were not increased, SQSTM1/
p62 protein levels were higher in LP-1/Cfz cells (Figure 
7F).
Kampmann and colleagues recently reported 
that knockdown of the 19S proteasome subunit genes 
desensitized U266 MM cells to carfilzomib [65]. Because 
the 19S regulator delivers substrates to the 20S catalytic 
core, they hypothesized that a loss in 19S function may 
lead to the selective accumulation of certain proteins. 
SQSTM1/p62 was one of the proteins that accumulated 
upon knockdown [65]. Congruent with their results, 
GSEA indicated that many of the proteasome 19S subunit 
genes were downregulated in LP-1/Cfz cells (Figure 
S7). Therefore, it is possible that this mechanism may 
contribute to increased SQSTM1/p62 levels in LP-1/
Cfz cells. However, as described below, we found that 
elevated protein synthesis was a contributing factor to 
the observed differences in SQSTM1/p62 levels. In this 
context, it is worth mentioning that knockdown of the 
Figure 7: Nrf2 activation in LP-1/Cfz cells confers resistance to carfilzomib. A. Knockdown of Nrf2 mRNA using two 
specific siRNAs (siNrf2 #1, siNrf2 #2) was accompanied by downregulation of GABARAPL1 mRNA (mean values of three qRT-PCR 
experiments). B. Knockdown of Nrf2 mRNA using two specific siRNAs (siNrf2 #1, siNrf2 #2) sensitizes LP-1/Cfz cells to carfilzomib. 
Cells were treated with the indicated concentrations of carfilzomib for 48 hours after transient transfection and cell viability was determined 
by alamarBlue assay. *, P < 0.001 vs negative siRNA control (siNeg, n = 3). C. Western blot analysis demonstrating significantly higher 
Nrf2 levels in the high salt fraction of LP-1/Cfz cell lysates (P < 0.001; n = 4). D. Cells were labeled with anti-Nrf2 antibody (Alexa Fluor 
488, green) and immunofluorescence staining was analyzed by confocal laser scanning microscopy. E. Cells were treated with the indicated 
concentrations of carfilzomib for 48 hours in the absence or presence of trigonelline (Trig, 1 μM), an inhibitor of Nrf2 nuclear import, and 
cell viability was determined by alamarBlue assay. *, P < 0.001 vs carfilzomib alone (n = 3). F. Western blot analysis showing increased 
SQSTM1 levels in LP-1/Cfz compared to parental LP-1 cells (P < 0.03; n = 5).
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19S proteasome subunit genes in U266 MM cells was not 
associated with substantially increased 20S chymotrypsin-
like protease activity selectively inhibited by carfilzomib 
[65]. Similarly, we did not detect a significant increase in 
20S chymotrypsin-like protease activity in LP-1/Cfz cells 
(data not shown), which was consistent with only a slight 
(~1.3-fold) increase in mRNA of the PSMB5-encoded 
constitutive β5 subunit targeted by carfilzomib (Figure 
S7). 
Kampmann and colleagues also identified genes 
involved in other nodes of the proteostasis network that 
desensitized U266 MM cells to carfilzomib, including 
Figure 8: Constitutive PERK-eIF2α signaling is associated with carfilzomib resistance in LP-1/Cfz cells. A. Western 
blot analysis showing that treatment with a PERK inhibitor (PERKi) lowers SQSTM1 levels in LP-1/Cfz (Cfz) and parental LP-1 cells (P 
< 0.05; n = 8). Cells were treated with MG-132 (15 µM) for 18 hours in the absence or presence of GSK2656157 (10 µM). B. Inhibition 
of PERK sensitizes LP-1/Cfz (top graph) but not KMS-11/Cfz cells (bottom graph) to carfilzomib. Cells were treated with the indicated 
concentrations of carfilzomib for 72 hours in the absence or presence of GSK2656157 (PERKi, 10 µM) and cell viability was determined 
by alamarBlue assay. *, P < 0.001 vs carfilzomib alone (n = 3). C. Western blot analysis showing that ISRIB treatment decreases SQSTM1 
levels (P < 0.03; n = 3) (top panels) and ATF4 levels (bottom panels) in LP-1/Cfz and parental LP-1 cells. Cells were treated with MG-132 
(15 µM) for 18 hours in the absence or presence of ISRIB (20 nM). D. Inhibition of eIF2α sensitizes LP-1/Cfz cells to carfilzomib. Cells 
were treated with the indicated concentrations of carfilzomib for 48 hours in the absence or presence of ISRIB (20 nM) and cell viability 
was determined by alamarBlue assay. *, P < 0.001 vs carfilzomib alone (n = 3).
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components of the eIF4F translation initiation complex 
(for example, EIF4E1) and the mechanistic target of 
rapamycin (MTOR) [65]. GSEA indicated that both of 
these pathways were downregulated in LP-1/Cfz cells: 
BIOCARTA_EIF4_PATHWAY (P < 0.001) (Figure 
S8A) and HALLMARK_ MTORC1_SIGNALING (P < 
0.009) (Figure S8B). Since activation of the PERK-ATF4 
pathway was also implicated by GSEA (Figure S3A) and 
PERK inhibits mTORC1 during induction of prosurvival 
autophagy [66], we assessed potential involvement of 
the PERK-eIF2α axis on SQSTM1/p62 translation. For 
these studies, we tested a highly selective inhibitor of 
PERK kinase activity (GSK2656157) [67] or another 
small molecule (ISRIB) which acts downstream and 
reverses the effects of phosphorylated eIF2α, thereby 
blocking ATF4 synthesis [68]. We found that PERK 
inhibition significantly reduced SQSTM1/p62 levels in 
LP-1/Cfz cells (Figure 8A) and sensitized LP-1/Cfz cells 
to carfilzomib (Figure 8B, top graph). By comparison, 
KMS-11/Cfz cells were not sensitized by PERK inhibition 
(Figure 8B, bottom graph). Treatment of LP-1/Cfz cells 
with ISRIB also decreased SQSTM1/p62 levels (Figure 
8C, top panels) (P < 0.03; n = 3) while concomitantly 
diminishing ATF4 levels (Figure 8C, bottom panels). 
Further, ISRIB treatment sensitized LP-1/Cfz cells to 
carfilzomib (Figure 8D). Thus, these results indicated 
that activation of the PERK-eIF2α pathway contributed 
to carfilzomib resistance. Moreover, they argued that 
SQSTM1/p62 translation occurs in part via an ATF4-like 
uORF-mediated mechanism (see Table S2 of ref. [69] for 
details of SQSTM1 uORF-containing transcripts).
Interestingly, we did not observe enrichment of 
IRE1 or ATF6 expression signatures corresponding to 
the other branches of the UPR in LP-1/Cfz cells. In 
fact, GSEA indicated that UPR signaling was attenuated 
(HALLMARK_UNFOLDED_PROTEIN_RESPONSE 
downregulated; Figure S8C). Therefore, the mechanistic 
basis for PERK activation in LP-1/Cfz cells is unknown. 
However, alternative signals for PERK activation have 
recently been uncovered [28, 29, 66, 70]. In particular, 
Gupta and colleagues described a noncanonical 
mechanism of PERK-Nrf2 activation in the absence of 
an endoplasmic reticulum stress response that results 
from an epithelial-to-mesenchymal transition (EMT) 
[28, 70]. Along these lines, enrichment of an EMT-like 
expression signature (HALLMARK_EPITHELIAL_
MESENCHYMAL_TRANSITION) was indicated by 
GSEA in LP-1/Cfz cells (Figure S8D), and decreased cell 
surface expression of E-cadherin compared to parental 
LP-1 cells (Figure S8E) is consistent with this as a 
contributory mechanism [71, 72].
Induction of Nrf2 target genes in LP-1/Cfz cells 
creates a positive feedback loop promoting 
eIF4E3-driven Nrf2 translation
Although Nrf2 levels are primarily governed by 
interaction with Keap1, accumulating evidence has 
highlighted the importance of de novo translation [22-24]. 
Therefore, we were prompted to compare Nrf2 synthesis 
in LP-1/Cfz and parental LP-1 cells. For these analyses, 
the cells were pretreated with MG-132 to prevent Nrf2 
proteasomal degradation. Under these conditions, we 
found significantly higher levels of Nrf2 in LP-1/Cfz 
cells (Figure 9A). We next tested the effects of 4EGI-1, 
an inhibitor of cap-dependent translation that prevents 
binding of eukaryotic initiation factor 4G (eIF4G) to 
eIF4E family members (the best characterized of which 
is eIF4E1) within the eIF4F translation initiation complex 
[73]. Inhibition of the eIF4E/eIF4G interaction eliminated 
the differences in Nrf2 levels between LP-1/Cfz and 
parental LP-1 cells (Figure 9B). The data thus indicated 
more active cap-dependent synthesis of Nrf2 in LP-1/Cfz 
cells. This result was contrary to the GSEA prediction 
that canonical eIF4F-mediated translation initiation was 
downregulated in LP-1/Cfz compared to parental LP-1 
cells (Figure S8A) and suggested the possible involvement 
of an alternative eIF4F cap-binding complex containing 
another member of the eIF4E family [74]. Along these 
lines, it has recently been appreciated that eIF4E3 interacts 
with eIF4G and competes with eIF4E1 to form a novel 
eIF4F cap-binding complex [37, 38]. Because this Nrf2 
target was upregulated at the mRNA level in LP-1/Cfz 
cells (Table S1A), we were interested in whether this was 
reflected at the level of eIF4E3 protein. We found that the 
increased EIF4E3 mRNA levels in LP-1/Cfz cells were 
accompanied by elevated eIF4E3 protein levels, whereas 
LP-1/Cfz and parental LP-1 cells had similar levels of 
eIF4E1 (Figure 9C).
Phosphorylation of eIF4E1 by mitogen-activated 
protein kinase interacting kinases (MNK) 1 and 2 
stimulates translation of a subset of mRNAs encoding 
proteins involved in cancer development and progression 
[75]. Gartenhaus and colleagues found that treatment 
of diffuse large B-cell lymphoma cells with an MNK 
inhibitor, CGP57380, reduced eIF4E1-driven translation 
and resulted in a compensatory increase in eIF4E3-driven 
translation [38]. To determine whether Nrf2 translation 
might be regulated via eIF4E1-eIF4E3 interplay, we 
investigated the effect of MNK inhibition on Nrf2 protein 
levels in LP-1/Cfz and parental LP-1 cells. We found that 
after CGP57380 treatment Nrf2 levels increased in both 
cases, with the levels in parental LP-1 cells approaching 
those in LP-1/Cfz cells (Figure 9B). These findings 
supported a role of eIF4E3 in the elevated synthesis of 
Nrf2 and the carfilzomib-resistant phenotype of LP-1/
Cfz cells. To directly test this, we transfected LP-1/Cfz 
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Figure 9: Acquisition of carfilzomib resistance in LP-1/Cfz cells is associated with eIF4E3-mediated translational 
reprogramming. A. Western blot analysis showing increased Nrf2 levels in LP-1/Cfz (Cfz) versus parental LP-1 cells (P < 0.002; n = 
18). Cells were treated with MG-132 (15 µM) for 18 hours. B. Synthesis of Nrf2 depends on eIF4E/eIF4G interaction (P < 0.003; n = 10) 
and is enhanced upon MNK inhibition (P < 0.03; n = 6). Cells were treated with MG-132 (15 µM) for 18 hours in the absence or presence of 
an eIF4E/eIF4G interaction inhibitor (4EGI-1, 50 µM) or an MNK inhibitor (CGP57380, 10 μM) and whole cell lysates were analyzed by 
Western blotting. C. Western blot analysis showing (from top to bottom) increased eIF4E3 levels (P < 0.001; n = 4), similar eIF4E1 levels, 
decreased FAM129A levels (P < 1 x 10-4; n = 7), and increased Rnd3 levels (P < 0.02; n = 6) in LP-1/Cfz versus parental LP-1 cells. Cells 
were treated with MG-132 (15 µM) for 18 hours. D. Western blot analysis showing that knockdown of EIF4E3 mRNA using two specific 
siRNAs was accompanied by decreased eIF4E3 and Nrf2 protein levels. E. Knockdown of EIF4E3 mRNA (siRNA #1) sensitizes LP-1/
Cfz cells to carfilzomib. Cells were treated with the indicated concentrations of carfilzomib for 48 hours after transient transfection and cell 
viability was determined by alamarBlue assay. *, P < 0.001 vs negative siRNA control (siNeg, n = 3).
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and parental LP-1 cells with two specific EIF4E3 siRNAs 
and a negative control siRNA. Figure 9D shows that Nrf2 
protein levels decreased with eIF4E3 protein knockdown. 
Moreover, eIF4E3 knockdown sensitized LP-1/Cfz cells to 
carfilzomib (Figure 9E).
We also examined whether the protein levels of 
two other novel Nrf2 targets involved in the control of 
cap-dependent translation initiation — RND3/RhoE and 
FAM129A/Niban — corresponded with the differential 
mRNA levels observed in LP-1/Cfz and LP-1 cells (Figure 
S4). FAM129A inhibits PERK-mediated phosphorylation 
of eIF2α [50]. Additionally, FAM129A and Rnd3 
reciprocally modulate the activity of 4E-BP1, an inhibitor 
of eIF4E1 [49, 50]. Briefly, the dephosphorylated form of 
4E-BP1 binds to eIF4E1, preventing binding of eIF4G and 
formation of the eIF4F complex. mTORC1 phosphorylates 
4E-BP1, leading to its dissociation from eIF4E1 which 
allows eIF4F formation and translation initiation [75]. 
FAM129A positively affects mTORC1 phosphorylation 
of 4E-BP1, thereby facilitating eIF4E1-driven translation 
[50]. In contrast, Rnd3 inhibits mTORC1 phosphorylation 
of 4E-BP1 which prevents 4E-BP1 disassociation from 
eIF4E1 and therefore inhibits eIF4E1 function [49]. 
This mechanism only pertains to eIF4E1 since 4E-BP1 
does not bind to eIF4E3 [74]. FAM129A protein levels 
were decreased in LP-1/Cfz cells corresponding with its 
diminished mRNA expression. Conversely, Rnd3 protein 
levels were increased in LP-1/Cfz cells concomitant with 
increased mRNA expression (Figure 9C). Collectively, 
these results are consistent with a potential positive 
feedback process associated with acquisition of 
carfilzomib resistance in LP-1/Cfz cells wherein initial 
activation of Nrf2 leads to direct and indirect regulation 
of target genes — including transcriptional upregulation 
of EIF4E3 — that facilitate enhanced eIF4E3-driven 
translation of Nrf2.
Increased EIF4E3 expression predicts Nrf2 target 
gene activation in minimal residual disease and 
relapsed MM patient samples
To assess the clinical relevance of our findings, 
we analyzed three independent publicly available gene 
expression datasets of MM patients. We first examined 
the gene expression profiles of chemoresistant minimal 
residual disease (MRD) and matched diagnostic samples 
from MM patients included in the GEM2010MAS65 
clinical trial (GEO accession number GSE70399) [76]. 
Notably, EIF4E3 expression was found to be increased 
in 5 out of 7 MRD samples (FC = 1.25; P = 0.013). 
When GSEA was applied to these 5 cases, significant 
upregulation of Nrf2 target genes (NFE2L2.V2 gene set) 
was observed in the persisting MRD cells (Figure 10A). 
As was found for LP-1/Cfz cells, UPR signaling was 
attenuated (HALLMARK_UNFOLDED_PROTEIN_ 
RESPONSE downregulated; Figure 10B). Moreover, 
GSEA predicted an inverse relationship with an 
enrichment pattern corresponding to genes regulated by 
EIF4E1 overexpression (Figure 10C).
We also examined patient-paired relapse and 
diagnostic samples from 17 MM patients treated with 
various regimens (GEO accession number GSE36824) 
[77]. EIF4E3 expression was increased in 4 out of 17 
cases of disease progression. GSEA indicated that Nrf2 
target genes (NFE2L2.V2 gene set) were upregulated 
during disease course in these 4 cases (Figure 11A). As 
for MRD cells with increased EIF4E3 expression, GSEA 
predicted lack of UPR stress in the relapsed MM cells 
(HALLMARK_UNFOLDED_PROTEIN_ RESPONSE 
downregulated; Figure 11B). These relapsed MM cells 
also had enrichment of an EMT-like expression signature 
(HALLMARK_EPITHELIAL_MESENCHYMAL_ 
TRANSITION; Figure 11C). Moreover, genes 
upregulated through activation of the mTORC1 complex 
were downregulated in these 4 cases (HALLMARK_
MTORC1_SIGNALING; Figure 11D). In addition, GSEA 
again predicted an inverse correlation with an EIF4E1-
specific gene expression signature (Figure 11E). Of the 
17 samples, GABARAPL1 expression was increased in 
5 cases during disease progression, two of which also 
had increased EIF4E3 expression. Performing GSEA 
on the combined EIF4E3 plus GABARAPL1 dataset (7 
out of 17 cases) indicated activation of Nrf2 signaling 
and yielded the same enrichment patterns for the other 
pathways identified for the 4 cases with increased EIF4E3 
expression (data not shown). 
On the other hand, when GSEA was performed on 
the 10 relapsed MM patient samples that did not exhibit 
increased EIF4E3 or GABARAPL1 expression, the exact 
opposite patterns of enrichment were obtained. In these 
cases, a positive correlation with EIF4E1-upregulated 
genes was observed during disease progression (Figure 
11F) concomitant with a prediction of increased mTORC1 
signaling (Figure S9A). Although a UPR was predicted 
(Figure S9B), Nrf2 target genes were downregulated 
(Figure S9C) and a reverse EMT-like expression signature 
(i.e., mesenchymal-to-epithelial transition) was suggested 
(Figure S9D). Therefore, these parameters appeared 
to separate the relapsed MM samples into two distinct 
groups: one, “LP-1/Cfz-like”, characterized by increased 
EIF4E3 (and/or GABARAPL1) expression having 
activation of the Nrf2 signaling pathway, and a second 
group (“eIF4E1-like”) exhibiting the opposite phenotype 
and pathway activation states in which enhanced eIF4E1-
driven translation was implied.
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Figure 10: Chemoresistant minimal residual disease (MRD) cells from MM patients have increased EIF4E3 expression 
and Nrf2 target gene signature enrichment. Microarray data was obtained from the Gene Expression Omnibus database (www.
ncbi.nlm.nih.gov/geo/; GEO accession number GSE70399) for matched MRD and diagnostic plasma cells from MM patients enrolled in 
the GEM2010MAS65 trial (ClinicalTrials.gov Identifier: NCT01237249). EIF4E3 expression in MRD cells versus baseline was analyzed 
with the GEO2R web tool (http://www.ncbi.nlm.nih.gov/geo/geo2r/) and was found to be increased in 5 out of 7 samples (average fold 
change = 1.25; P = 0.013). A. GSEA indicated that Nrf2 target genes were upregulated in MRD cells. Gene set: NFE2L2.V2 (M2870). B. 
GSEA indicated that genes upregulated during the unfolded protein response were downregulated in MRD cells. Gene set: HALLMARK_
UNFOLDED_PROTEIN_RESPONSE (M5922). C. GSEA indicated that genes downregulated in primary human mammary epithelial 
cells upon overexpression of EIF4E1 were upregulated in MRD cells. Gene set: EIF4E_DN (M2790).
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Elevated expression of EIF4E3 is prognostic of 
poor survival
LP-1 MM cells contain the t(4;14) chromosomal 
translocation that activates a histone methyltransferase 
encoded by the WHSC1 gene (also known as MMSET) 
[78], which is consistently associated with poor outcome 
[79]. Using the UAMS-70 prognostic gene signature, 
Shaughnessy and colleagues separated WHSC1-positive 
MM patients into higher-risk and lower-risk subgroups 
[80]. We were curious to know whether increased 
expression of EIF4E3 was prognostic for decreased 
overall survival of WHSC1-positive MM patients. Using 
Figure 11: Gene expression signatures of MM cells associated with increased EIF4E3 expression during progression 
of disease. Microarray data was obtained from the GEO database (GEO accession number GSE36824) for patient-paired relapse and 
diagnostic samples from 17 patients treated with various regimens. EIF4E3 expression was increased in 4 out of 17 cases. A. GSEA 
indicated that Nrf2 target genes were upregulated during disease course in these cases. Gene set: NFE2L2.V2 (M2870). B. GSEA indicated 
that genes upregulated during the UPR were downregulated. Gene set: HALLMARK_UNFOLDED_PROTEIN_RESPONSE (M5922). 
C. These patients had enrichment of an EMT-like expression signature. Gene set: HALLMARK_EPITHELIAL_MESENCHYMAL_ 
TRANSITION (M5930). D. Genes upregulated through activation of the mTORC1 complex were also downregulated in these cases. Gene 
set: HALLMARK_MTORC1_SIGNALING (M5924). E. GSEA indicated that genes upregulated in primary human mammary epithelial 
cells upon overexpression of EIF4E1 were downregulated during disease course in relapse cells with increased EIF4E3 expression. Gene 
set: EIF4E_UP (M2791). F. GSEA of patient-paired relapse and diagnostic samples without increased EIF4E3 and/or GABARAPL1 
expression (10 out of 17 cases) showed enrichment of the EIF4E_UP signature. See also Figure S9.
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the PROGgeneV2 prognostic biomarker identification 
tool [81] as previously described [11], we performed 
a Cox proportional hazards regression analysis on 546 
newly diagnosed MM patients treated on the UARK 98-
026 TT2 and UARK 2003-033 TT3 clinical trials [80]. 
The hazard ratio (HR) for patients with high versus low 
WHSC1 expression was 1.3 (95% confidence interval 
(CI), 1.1-1.54; P < 0.002). As shown in Figure 12A, high-
level coexpression of EIF4E3 resulted in increased risk 
of mortality (HR = 1.6; 95% CI, 1.17-2.21; P < 0.004), 
which was higher than the increased risk score predicted 
by high-level coexpression of EIF4E1 (HR = 1.45; 95% 
CI, 1.04-2.02; P < 0.03) (Figure 12B).
DISCUSSION
Despite improved outcomes with the introduction 
of novel agents such as proteasome inhibitors to MM 
treatment regimens over the past decade, patients 
inevitably succumb to their disease because the MM 
cells become resistant to the drugs [1]. MM cells can 
develop resistance to proteasome inhibitors through a 
variety of mechanisms [4]. However, it is still unclear 
which mechanisms explain clinical proteasome inhibitor 
resistance. 
In this paper we report the establishment of a new 
carfilzomib-resistant MM cell line derivative, LP-1/Cfz, 
in which elevated levels of the SQSTM1/p62 ubiquitin-
binding cargo receptor were associated with carfilzomib 
resistance that comprised both prosurvival autophagy 
and Nrf2 pathway activation. Our results support a model 
wherein activation of the SQSTM1/p62-Nrf2 pathway 
— in concert with the PERK-eIF2α/ATF4 axis — directs 
reprogramming of MM cells, modulating redox and energy 
homeostasis via elevated FAO and inducing prosurvival 
autophagy involving GABARAPL1 upregulation [15, 26-
29, 34-36]. We suggest that the increased SQSTM1/p62 
levels allow newly synthesized Nrf2 to escape Keap1-
mediated sequestering in the cytoplasm [13, 14], resulting 
in the regulation of a subset of its target genes, including 
EIF4E3, which in turn facilitate enhanced translation of 
Nrf2 and establish a positive feedback loop. While further 
mechanistic studies are required to fully define the role 
played by SQSTM1/p62 in carfilzomib resistance, we 
demonstrated the direct involvement of Nrf2 by genetic 
and pharmacologic inhibition and a contribution of PERK 
using two highly selective small-molecule inhibitors of the 
PERK-eIF2α axis [67, 68].
Previously we reported that acquisition of 
carfilzomib resistance in KMS-11/Cfz and KMS-34/Cfz 
MM cells was associated with prosurvival autophagy 
involving SQSTM1/p62 [11]. Comparative analyses 
of KMS-11/Cfz cells herein also revealed activation of 
Nrf2 target genes (Figure 1B). Carfilzomib resistance 
in KMS-11/Cfz cells is associated with KLF4-mediated 
transcriptional upregulation of SQSTM1 expression [11]. 
Others have described the establishment of a positive 
feedback loop in which Nrf2 transcriptionally activates 
SQSTM1 [13, 14] (highlighted in Figure S1B). We note 
that KLF4 is also an Nrf2 target gene (Table S1B), so we 
envision a model in KMS-11/Cfz cells wherein KLF4 
and Nrf2 cooperate to transcriptionally maintain elevated 
SQSTM1/p62 levels. 
GSEA revealed that activation of the PERK-eIF2α 
axis in LP-1/Cfz cells was not associated with induction of 
a UPR (Figure S8C). Gupta and colleagues have described 
Figure 12: Prognostic value of EIF4E3 expression in MM patient survival outcomes. Kaplan-Meier survival plots of 546 
newly diagnosed patients with MM consisting of 351 cases enrolled on total therapy 2 (TT2) and 195 patients enrolled in total therapy 3 
(TT3) which incorporates bortezomib into the induction phase of the TT2 transplant regimen (GEO accession number GSE2658) were 
created using PROGgeneV2. A. Coexpression of WHSC1 and EIF4E3. B. Coexpression of WHSC1 and EIF4E1. Cohorts were divided at 
the 75th percentile of mean gene expression. HR, hazard ratio determined by Cox proportional hazards model.
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a noncanonical mechanism of PERK-Nrf2 activation in the 
absence of an endoplasmic reticulum stress response that 
involves an EMT-like adaptation [28, 70]. Enrichment of 
an EMT-like expression signature was predicted by GSEA 
for LP-1/Cfz cells (Figure S8D) and for relapsed MM 
patient samples with increased EIF4E3 expression (Figure 
11C). Further investigation of an EMT-related mechanism 
is underway and our preliminary studies are suggestive 
of crosstalk among Nrf2, ERBB2 and hypoxia signaling 
pathways [82, 83]. Indeed, our ongoing examination of 
LP-1/Cfz cells indicates that they exhibit intermediate 
EMT-like characteristics [84]. Of relevance in this regard, 
a recent study by Orlowski and colleagues identified 
low levels of TJP1 encoding the epithelial marker tight 
junction protein 1 (also known as zonula occludens 1) as 
a determinant of myeloma proteasome inhibitor resistance 
[85]. During EMT, intercellular junctions are disrupted 
and TJP1 is coordinately downregulated with E-cadherin 
[86]. Interestingly, TJP1 expression was decreased in 
KMS-11/Cfz and KMS-34/Cfz cells but increased in 
LP-1/Cfz cells (our unpublished results). While Nrf2 
has been demonstrated to downregulate E-cadherin 
expression [72], it has been implicated in the upregulation 
of TJP1 expression [87]. Intriguingly, Orlowski and 
colleagues reported that proteasome inhibitor sensitivity 
associated with increased TJP1 expression was due to 
suppression of expression of the PSMB8 gene encoding 
the immunoproteasome β5i/LMP7 (chymotrypsin-like) 
subunit targeted by carfilzomib and bortezomib as well as 
the PSMB9 gene encoding the β1i/LMP2 (caspase-like) 
subunit that is also targeted by bortezomib [85]. In accord 
with their findings of an inverse relationship with TJP1 
expression, both PSMB8 and PSMB9 were downregulated 
in LP-1/Cfz cells (Figure S7). In their model, this 
apparently occurred through TJP1-mediated suppression 
of EGFR/ERBB2 signaling [85]. As TJP1 also interacts 
with GABARAPL1 through the CUL3-KBTBD6/
KBTBD7 ubiquitin ligase in the autophagy network 
[53], we speculate that complex interplay between Nrf2-
GABARAPL1/TJP1 and ERBB2 signaling pathways may 
underlie the carfilzomib-resistant LP-1/Cfz phenotype 
(Figure S3C, S3D) [45, 46, 88, 89].
Carfilzomib resistance in the KMS-11/Cfz and 
KMS-34/Cfz models was characterized by a partial 
reversal of plasma cell maturation [11]. These results are 
in line with the findings of others showing that primary 
MM cells are capable of dedifferentiating into a less 
mature MM phenotype conferring experimental and 
clinical drug resistance [90-92]. It is notable that LP-1/Cfz 
cells did not fully recapitulate this pattern. Parental LP-1 
cells exhibit a membrane phenotype that is intermediate 
between late B lymphocytes and plasma cells based on 
MHC class II antigen expression [39]. Like the KMS-11/
Cfz and KMS-34/Cfz carfilzomib-resistant MM models 
[11], acquisition of carfilzomib resistance in LP-1/
Cfz cells was accompanied by decreased expression of 
SLAMF7 encoding the plasma cell-specific CD319 cell 
surface marker, reflecting a partial reversal of plasma 
cell maturation (Table S1A). Conversely, MHC class II 
antigen expression was diminished, which is reminiscent 
of plasmacytic differentiation (Table S2A). In this latter 
respect, LP-1/Cfz cells might resemble in part the situation 
observed in mantle cell lymphoma where bortezomib 
resistance increased with plasmacytic differentiation [93]. 
Accordingly, LP-1/Cfz cells may have attained the ‘‘sweet 
spot’’ maturation stage intrinsically less susceptible 
to proteasome inhibition proposed by Tiedemann and 
colleagues [92]. 
Our results indicating a role of Nrf2 activation in 
experimental carfilzomib resistance parallel those of 
others wherein Nrf2 target gene activation was associated 
with poor responsiveness to bortezomib in mouse and 
human MM models [94, 95]. In this regard, both LP-1/
Cfz and KMS-11/Cfz exhibit some cross-resistance to 
bortezomib (Figure S1). In that various regimens were 
used in the treatment of the MM patients that we analyzed 
[76, 77, 80], we cannot conclude that increased EIF4E3 
expression can be used as a specific indicator of clinical 
carfilzomib resistance. Nonetheless, the finding that 
EIF4E3 expression is increased in certain chemoresistant 
minimal residual disease and relapsed MM patient 
samples and is predictive of Nrf2 target gene activation, 
strongly suggests that the Nrf2-EIF4E3 axis and eIF4E3-
driven translation contributes to MM drug resistance 
mechanisms in the clinical setting. On the other hand, 
lack of EIF4E3 expression in relapsed samples was able 
to distinguish a second group of MM patient samples 
exhibiting the opposite phenotype and pathway activation 
states in which enhanced eIF4E1-driven translation was 
indicated. These findings are consistent with the results 
of other studies demonstrating a role of eIF4E1 in MM 
biology and proteasome inhibitor resistance [65, 96-98]. It 
is particularly noteworthy therefore — especially in view 
of the documented oncogenic activity of EIF4E1 [75] — 
that WHSC1-expressing MM patients with high EIF4E3 
expression had less favorable outcomes than those with 
high EIF4E1 expression (Figure 12). 
In summary, our finding of noncanonical SQSTM1/
p62-Nrf2 pathway activation adds to the growing 
appreciation from our work and others that carfilzomib 
resistance in MM can arise via multiple mechanisms 
[10, 11, 65, 85, 99]. MM is heterogeneous in its etiology 
and progression so these varied results are not entirely 
unexpected [100]. Collectively, our studies suggest 
several approaches to sensitize drug-resistant MM cells 
to carfilzomib [10, 11]. In particular, the data presented 
herein support the development of novel therapies 
targeting the SQSTM1/p62-Nrf2 pathway for a subgroup 
of advanced stage MM patients with eIF4E3-driven 
translation.
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MATERIALS AND METHODS
Cell culture
LP-1 and KMS-11 MM cells were a kind gift from 
Dr. P. Leif Bergsagel (Mayo Clinic, Scottsdale, AZ) 
[101]. Cells were cultured in RPMI 1640 with GlutaMAX 
(Thermo Fisher Scientific) supplemented with 10% fetal 
bovine serum (Cambrex BioScience), 100 U/ml penicillin 
and 100 μg/ml streptomycin. Cultures were maintained at 
37°C in a humidified atmosphere containing 5% CO2.
Antibodies and reagents
The following antibodies were used: anti-ATF4/
CREB-2 (c-20) (Santa Cruz Biotechnology, Cat. No. sc-
200); anti-eIF4E1 (P-2) (Santa Cruz Biotechnology, Cat. 
No. sc-9976); anti-eIF4E3 (Proteintech, Cat. No. 17282-1-
AP); anti-FAM129A/Niban (Signalway Antibody, Cat. No. 
21401-2); anti-Keap1 (H-190) (Santa Cruz Biotechnology, 
Cat. No. sc-33569); anti-Nrf2 (H-300) (Santa Cruz 
Biotechnology, Cat. No. sc-13032); anti-RhoE/Rnd3 clone 
4 (EMD Millipore Corporation, Cat. No 05-723); anti-
SQSTM1/p62 (Clone 3) mouse mAb (BD Transduction 
Laboratories, Cat. No. 610832); and anti-α-tubulin mouse 
mAb (DM1A) (EMD Millipore Corporation, Cat. No. 
CP06). Carfilzomib (Cat. No. A-1098) was obtained 
from Active Biochem; chloroquine (Cat. No. S4157) and 
GSK2656157 (Cat. No. S7033) were purchased from 
Selleck Chemicals; (S)-4-carboxyphenylglycine (Cat. 
No. 0323), CGP57380 (Cat. No. 2731), 4EGI-1 (Cat. 
No. 4800) and MG-132 (Cat. No. 1748) were ordered 
from Tocris Bioscience; etomoxir (Cat. No. 11969) 
was obtained from Cayman Chemical; and trigonelline 
hydrochloride (Cat. No. T5509-1G) was from Sigma-
Aldrich.
Microarray gene expression analysis and 
quantitative real-time qRT-PCR validation
Total RNA was isolated with the miRNeasy 
mini kit (Qiagen, Cat. No. 217004). Microarray gene 
expression analysis of triplicate samples was carried 
out by Expression Analysis, Inc. (Durham, NC) using 
Affymetrix GeneChip Human Genome U133 Plus 2.0 
arrays. The data have been deposited in GEO (http://
www.ncbi.nlm.nih.gov/geo/) under accession number 
GSE78069. Reverse transcription was performed with 
the SuperScript VILO cDNA synthesis kit (Thermo 
Fisher Scientific, Cat. No. 11754250). Real-time qRT-
PCR was performed using the Power SYBR Green 
PCR master mix (Thermo Fisher Scientific, Cat. No. 
4367659) on an ABI Prism 7000 Sequence Detection 
System (Applied Biosystems) as previously described 
[10, 11]. Primers synthesized by Sigma-Aldrich included: 
EEF1A2, forward, GTGTACAAGATTGGCGGCAT, 
reverse, GATGTTCACTGGCGCAAAGG; FAM129A, 
forward, TACATCCGAGGGAAAACTGAGG, reverse, 
GCCACAGAGTACTGACGACT; GABARAPL1, 
forward, AGGAGGACCATCCCTTTGAGT, 
reverse, TCTACAATCACGGGGACCCT; NFE2L2, 
forward, CGGTATGCAACAGGACATTG, 
reverse, TGGCTTCTGGACTTGGAACC; RND3, 
forward, GTCGGCTGCAAGTCTGATCT, reverse, 
CCATATTTGCCCCCTGGTCA; and ACTB, 
forward, GGACTTCGAGCAAGAGATGG, reverse, 
AGCACTGTGTTGGCGTACAG.
Chromatin immunoprecipitation (ChIP)
ChIP was performed on the GABARAPL1 promoter 
region with 20 µg total chromatin and 5 µg of anti-Nrf2 
antibody using the SimpleChIP Enzymatic Chromatin 
IP Kit (Magnetic Beads) (Cell Signaling, Cat. No. 9003) 
as previously described [11], and 4% of the precipitated 
material was used per qPCR reaction. Background ChIP 
levels were obtained using 5 µg of anti-Keap1 antibody. 
Primers used were: GABARAPL1 promoter region, 
forward, CCGTGTCCTTCATCTGACTCC, reverse, 
TCGCTCCTGAACAGCAACAT.
siRNA transfection
For RNA interference, LP-1/Cfz and parental LP-1 
cells were transiently transfected with Nrf2 siRNAs 
(SI03246950 [#1] and SI03246614 [#2]; QIAGEN, 
FlexiTube GeneSolution for NFE2L2, Product No. 
1027416, Cat. No. GS4780), eIF4E3 siRNAs (s50217 
[#1] and s50218 [#2]; Thermo Fisher Scientific Silencer 
Select) or a negative control siRNA (QIAGEN, ALLStars 
negative control siRNA, Cat. No. 1027281) using the 
HiPerFect transfection reagent (QIAGEN). Briefly, 2 x 
106 cells per ml were seeded into 24 well plates in 100 μl 
aliquots. Each well received a mixture of siRNAs (750 ng) 
and HiPerFect reagent (6 μl) in 100 μl serum-free culture 
medium preincubated for 15 minutes. After 5 hours, the 
cells were diluted to 6 x 105 per ml in complete medium. 
Cells (3 x 105 per ml) were seeded into 96 well plates and 
treated with a range of carfilzomib concentrations. After 
48 hours, cell growth was measured and cells (3 x 105) 
were lysed for total RNA isolation and qRT-PCR analysis 
of Nrf2 and GABARAPL1 mRNA levels or western blot 
analysis of eIF4E3 and Nrf2 protein levels as indicated. 
The data were normalized to ACTB mRNA levels.
Oncotarget66380www.impactjournals.com/oncotarget
Cytotoxicity assay
Cells were treated with carfilzomib and agents at the 
indicated concentrations and cell growth was measured 
using the alamarBlue cell viability and proliferation 
reagent (Thermo Fisher Scientific) as previously described 
[10, 11].
Measurement of NADPH
NADPH was measured using an NADP/NADPH 
Quantitation Kit (Sigma-Aldrich, Cat. No. MAK038) 
according to the manufacturer’s instructions [102].
Measurement of FAO
Oxygen consumption rate was measured using the 
XF24 Extracellular Flux Analyzer (Seahorse Bioscience) 
as previously described [103]. FAO was determined by 
XF Cell Mito Stress Test (Cat. No. 103010-100) using the 
XF Palmitate-BSA FAO substrate (Cat. No. 102720-100) 
in the absence or presence of etomoxir according to the 
manufacturer’s instructions.
ROS and autophagy detection
Cells (4 x 105 per ml) were seeded into 12 well 
plates in 500 μl aliquots and treated with 0, 25 or 50 nM 
carfilzomib for 18 hours. H2O2-associated ROS levels were 
quantified by flow cytometry using 488 nm excitation 
and 530/30 nm band pass filter detection after labeling 
with CM-H2DCFDA (Thermo Fisher Scientific, Cat. No. 
C6827) for 60 minutes at 37oC. O2
.- levels were quantified 
by flow cytometry using 488 nm excitation and 585/42 
nm band pass detection after labeling with MitoSOX 
Red (Thermo Fisher Scientific, Cat. No. M36008) for 
30 minutes at 37oC. Flow cytometry was performed 
on a FACSAria instrument equipped with FACSDiva 
software (BD Biosciences). Dead cells were identified by 
SYTOX Blue staining (Thermo Fisher Scientific, Cat. No. 
S34857) and excluded from analysis. Data were analyzed 
with FlowJo Mac v10.0.2 (Tree Star) and presented on a 
bivariate plot versus 633 nm excitation and 780/60 nm 
band pass filter detection.
Autophagy was measured with the Cyto-
ID autophagy detection kit (Enzo, Cat. No. ENZ-
51031-K200) using a FACSAria instrument, and data 
were analyzed with FlowJo Mac v10.0.2 as previously 
described [11]. 
Cellular fractionation
Nuclear and cytoplasmic extracts were prepared for 
western blot analysis essentially as described [64].
Confocal microscopy
Immunofluorescence confocal microscopy was 
performed as previously described [11]. In brief, cells 
(2.5 x 105) were centrifuged onto a microscope slide at 
1,000 rpm for 5 minutes using a Shandon Cytospin 4 
instrument. The cells were then immediately fixed in 
3.7% formaldehyde for 5 minutes at room temperature 
and permeabilized with 0.5% Triton X-100 in phosphate-
buffered saline (PBS) for 15 minutes at room temperature. 
Following permeabilization, the cells were rinsed with 
PBS and blocked in PBS containing 10% goat serum and 
0.01% Triton X-100 for 1 hour at room temperature. The 
cells were then incubated with anti-Nrf2 antibody diluted 
to a final concentration of 0.4 µg/ml, in PBS containing 
1% goat and 0.01% Triton X-100 for 1 hour at room 
temperature. The cells were rinsed with PBS and then 
incubated with Alexa Fluor 488-conjugated goat anti-
rabbit secondary antibody (Thermo Fisher Scientific, 
Cat. No. R37116) diluted 1:500 in PBS containing 1% 
goat serum and 0.01% Triton X-100 for 1 hour at room 
temperature. The cells were rinsed with PBS and mounted 
with Fluoromount G (Electron Microscopy Sciences). 
Imaging analysis was performed on a Cell Observer SD 
spinning disk confocal system equipped with Zen software 
(Carl Zeiss Microscopy).
Proteasome activity
Proteasome chymotrypsin-like activity was 
measured by cleavage of a specific luminogenic 
proteasome substrate (succinyl-leucine-leucine-valine-
tyrosine-aminoluciferin) using the Proteasome-Glo 
Chymotrypsin-Like Assay according to the manufacturer’s 
instructions (Promega Corporation, Cat. No. G8660). 
Luminescence intensities were quantified with a Gemini 
XPS microplate spectrofluorometer equipped with 
SoftMax Pro software (Molecular Devices Corp.).
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